No Data
Is ADC Therapeutics SA (NYSE:ADCT) Worth US$2.0 Based On Its Intrinsic Value?
ADC Spikes After Enrollment Update on Confirmatory Trial for Lymphoma Therapy
ADC Completes Enrollment in Late-Stage Zynlonta Combination Trial
ADC Therapeutics Completes Enrollment in LOTIS-5 Trial
ADC Therapeutics Price Target Maintained With a $10.00/Share by Guggenheim
ADC Therapeutics Stock Plunges 36% Amid Zynlonta Data Release